^
    17h
    Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P3, N=874, Recruiting, Shanghai Shengdi Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    6d
    Sintilimab-induced delayed-onset toxic epidermal necrolysis in a patient with gastric carcinoma: a case report and literature review. (PubMed, Front Oncol)
    We report a case of a patient with gastric carcinoma who developed delayed-onset TEN after receiving four cycles of neoadjuvant sintilimab combined with the SOX regimen (S-1 and oxaliplatin)...Early recognition and timely immunosuppressive treatment are essential for favorable outcomes. Further investigation into the mechanisms and predictive factors of PD-1 inhibitor-induced TEN is warranted.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FASLG (Fas ligand)
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    6d
    A Case of Esophagogastric Junction Cancer Treated with Perioperative Nivolumab Therapy (PubMed, Gan To Kagaku Ryoho)
    Neoadjuvant chemotherapy with docetaxel plus S-1 regimen was administered, resulting in stable disease(SD)...The patient continued adjuvant nivolumab therapy postoperatively and remained disease-free. This case highlights the potential role of perioperative immunotherapy with nivolumab in MSI-H EGJ cancers and the promise of personalized treatment strategies.
    Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • docetaxel • Teysuno (gimeracil/oteracil/tegafur)
    8d
    Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=88, Recruiting, Ruijin Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative
    |
    Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    8d
    Efficacy and safety of SOX regimen combined with Pembrolizumab in the treatment of metastatic gastric cancer (PubMed, Zhonghua Zhong Liu Za Zhi)
    Objective: To investigate the clinical efficacy, toxicity and prognosis of SOX regimen (Oxaliplatin plus S-1) combined with Pabolizumab in the treatment of patients with metastatic gastric cancer...There was no statistical difference in the incidence [67.9% (38/56) in chemotherapy group vs 78.4% (40/51) in combination group] of grade Ⅲ-Ⅳ toxicity between the two groups (P=0.219). In patients with PD-L1 CPS ≥1 or all enrolled patients, compared with chemotherapy alone, SOX regimen combined with pembrolizumab in the treatment of metastatic gastric cancer can significantly improve ORR, prolong PFS and OS, improve prognosis and quality of life, while the toxicity has not increased significantly.
    Retrospective data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    14d
    STAR-02: Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Shandong Provincial Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    15d
    LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study (clinicaltrials.gov)
    P2, N=74, Recruiting, Ruijin Hospital
    New P2 trial
    |
    CLDN18 (Claudin 18)
    |
    paclitaxel • Kaitanni (cadonilimab) • Teysuno (gimeracil/oteracil/tegafur)
    15d
    Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S-1, Irinotecan, and Oxaliplatin as Second-Line Chemotherapy After Gemcitabine Plus Nab-Paclitaxel for Unresectable Pancreatic Cancer. (PubMed, J Hepatobiliary Pancreat Sci)
    S-IROX may be an effective and safe second-line option after GnP, particularly for locally advanced PC.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur) • Onivyde (nanoliposomal irinotecan)
    15d
    Alternate-day Capecitabine Plus Trastuzumab for Frail HER2-positive Gastric Cancer: A Pilot Case Series. (PubMed, In Vivo)
    Alternate-day capecitabine without a reduction in the daily dose is a feasible treatment modification option, including in combination with trastuzumab, for managing patients with HER2-positive gastric cancer who are frail or pre-frail.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    21d
    Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction (clinicaltrials.gov)
    P2, N=116, Recruiting, Xijing Hospital | Trial primary completion date: Mar 2026 --> May 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    albumin-bound paclitaxel • oxaliplatin • Hetronifly (serplulimab) • Teysuno (gimeracil/oteracil/tegafur)
    21d
    Single-Arm, Phase II Clinical Study of Ipalolimab and Tovorelimab in Combination with Regorafenib and Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (G/GEJ) Adenocarcinoma (ChiCTR2600120217)
    P2, N=35, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    capecitabine • Stivarga (regorafenib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    21d
    A single-center prospective clinical study based on ctDNA-MRD monitoring to guide postoperative adjuvant chemotherapy for gastric cancer. (ChiCTR2600118969)
    P=N/A, N=120, Beijing Friendship Hospital ,Capital Medical University; Beijing Friendship Hospital ,Capital Medical University
    New trial • Circulating tumor DNA
    |
    Teysuno (gimeracil/oteracil/tegafur)